171 related articles for article (PubMed ID: 33451301)
1. Post-status epilepticus treatment with the Fyn inhibitor, saracatinib, improves cognitive function in mice.
Luo XM; Zhao J; Wu WY; Fu J; Li ZY; Zhang M; Lu J
BMC Neurosci; 2021 Jan; 22(1):2. PubMed ID: 33451301
[TBL] [Abstract][Full Text] [Related]
2. Role of the Fyn-PKCδ signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy.
Sharma S; Carlson S; Puttachary S; Sarkar S; Showman L; Putra M; Kanthasamy AG; Thippeswamy T
Neurobiol Dis; 2018 Feb; 110():102-121. PubMed ID: 29197620
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy.
Sharma S; Carlson S; Gregory-Flores A; Hinojo-Perez A; Olson A; Thippeswamy T
Neurobiol Dis; 2021 Aug; 156():105410. PubMed ID: 34087381
[TBL] [Abstract][Full Text] [Related]
4. Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo.
Du G; Wang J; Zhang T; Ding Q; Jia X; Zhao X; Dong J; Yang X; Lu S; Zhang C; Liu Z; Zeng Z; Safadi R; Qi R; Zhao X; Hong Z; Lu Y
Cell Death Dis; 2020 Feb; 11(2):118. PubMed ID: 32051399
[TBL] [Abstract][Full Text] [Related]
5. Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model.
Smith LM; Zhu R; Strittmatter SM
Neuropharmacology; 2018 Mar; 130():54-61. PubMed ID: 29191754
[TBL] [Abstract][Full Text] [Related]
6. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice.
Kaufman AC; Salazar SV; Haas LT; Yang J; Kostylev MA; Jeng AT; Robinson SA; Gunther EC; van Dyck CH; Nygaard HB; Strittmatter SM
Ann Neurol; 2015 Jun; 77(6):953-71. PubMed ID: 25707991
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase Fyn promotes osteoarthritis by activating the β-catenin pathway.
Li K; Zhang Y; Zhang Y; Jiang W; Shen J; Xu S; Cai D; Shen J; Huang B; Li M; Song Q; Jiang Y; Liu A; Bai X
Ann Rheum Dis; 2018 Jun; 77(6):935-943. PubMed ID: 29555825
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Synaptic Density Imaging with
Toyonaga T; Smith LM; Finnema SJ; Gallezot JD; Naganawa M; Bini J; Mulnix T; Cai Z; Ropchan J; Huang Y; Strittmatter SM; Carson RE
J Nucl Med; 2019 Dec; 60(12):1780-1786. PubMed ID: 31101744
[No Abstract] [Full Text] [Related]
9. The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
Sanz-Blasco S; Bordone MP; Damianich A; Gomez G; Bernardi MA; Isaja L; Taravini IR; Hanger DP; Avale ME; Gershanik OS; Ferrario JE
Mol Neurobiol; 2018 Jun; 55(6):5125-5136. PubMed ID: 28840468
[TBL] [Abstract][Full Text] [Related]
10. The Fyn kinase inhibitor, AZD0530, suppresses mouse alcohol self-administration and seeking.
Morisot N; Berger AL; Phamluong K; Cross A; Ron D
Addict Biol; 2019 Nov; 24(6):1227-1234. PubMed ID: 30536923
[TBL] [Abstract][Full Text] [Related]
11. Targeting Fyn Kinase in Alzheimer's Disease.
Nygaard HB
Biol Psychiatry; 2018 Feb; 83(4):369-376. PubMed ID: 28709498
[TBL] [Abstract][Full Text] [Related]
12. Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy.
Tang SJ; Fesharaki-Zadeh A; Takahashi H; Nies SH; Smith LM; Luo A; Chyung A; Chiasseu M; Strittmatter SM
Acta Neuropathol Commun; 2020 Jul; 8(1):96. PubMed ID: 32611392
[TBL] [Abstract][Full Text] [Related]
13. The role of necroptosis in status epilepticus-induced brain injury in juvenile rats.
Cai Q; Gan J; Luo R; Qu Y; Li S; Wan C; Mu D
Epilepsy Behav; 2017 Oct; 75():134-142. PubMed ID: 28863321
[TBL] [Abstract][Full Text] [Related]
14. Early treatment with C1 esterase inhibitor improves weight but not memory deficits in a rat model of status epilepticus.
Schartz ND; Sommer AL; Colin SA; Mendez LB; Brewster AL
Physiol Behav; 2019 Dec; 212():112705. PubMed ID: 31628931
[TBL] [Abstract][Full Text] [Related]
15. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage.
White HS; Alex AB; Pollock A; Hen N; Shekh-Ahmad T; Wilcox KS; McDonough JH; Stables JP; Kaufmann D; Yagen B; Bialer M
Epilepsia; 2012 Jan; 53(1):134-46. PubMed ID: 22150444
[TBL] [Abstract][Full Text] [Related]
16. Differential Impact of Severity and Duration of
Gage M; Putra M; Gomez-Estrada C; Golden M; Wachter L; Gard M; Thippeswamy T
Front Cell Neurosci; 2021; 15():772868. PubMed ID: 34720886
[TBL] [Abstract][Full Text] [Related]
17. miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.
Jin J; Sun Z; Yang F; Tang L; Chen W; Guan X
Arch Biochem Biophys; 2018 May; 645():54-60. PubMed ID: 29550144
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage.
Brewster AL; Lugo JN; Patil VV; Lee WL; Qian Y; Vanegas F; Anderson AE
PLoS One; 2013; 8(3):e57808. PubMed ID: 23536771
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F
Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946
[TBL] [Abstract][Full Text] [Related]
20. Carvacrol after status epilepticus (SE) prevents recurrent SE, early seizures, cell death, and cognitive decline.
Khalil A; Kovac S; Morris G; Walker MC
Epilepsia; 2017 Feb; 58(2):263-273. PubMed ID: 28084627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
